Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.
Tirzepatide was associated with lower incidences of cardiovascular events and all-cause mortality compared to semaglutide in patients with type 2 diabetes.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
This study compared cardiovascular outcomes between tirzepatide and semaglutide in patients with type 2 diabetes (T2D). The analysis involved 271,685 patients in each group, focusing on the incidence of a composite of cardiovascular events and all-cause mortality. Tirzepatide was associated with lower incidences of these outcomes compared to semaglutide.
Abstract
<h4>Purpose</h4>tirzepatide is associated with greater glycemic control and weight reduction compared to semaglutide in patients with T2D. Tirzepatide has also been recently shown to be non-inferior to dulaglutide in cardiovascular risk reduction among patients with T2D. Whether tirzepatide is more or less effective than semaglutide for cardioprotection is underexplored.<h4>Methods</h4>The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026. One-to-one propensity score matching was applied to control for possible confounding covariates.<h4>Results</h4>two well-matched cohorts (<i>N</i> = 271,685 for each) were analyzed. Compared to the semaglutide group, the tirzepatide group had lower incidences of the primary composite outcome (4.6% vs. 5.5%; absolute risk difference [ARD] -0.9%, 95% confidence interval [CI] -1.01 to -0.77; hazard ratio [HR] 0.9, 95% CI 0.92─0.96) and all-cause mortality (0.6% vs. 0.9%; ARD - 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84).<h4>Conclusion</h4>Tirzepatide was associated with lower risk of a composite of outcome of cardiovascular events as well as all-cause mortality compared to semaglutide in patients with T2D.<h4>Clinical trial registration</h4>Clinical trial number: not applicable.<h4>Supplementary information</h4>The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02087-z.
Background
This paper addresses the comparative effectiveness of tirzepatide versus semaglutide regarding cardiovascular outcomes in patients with type 2 diabetes (T2D). Previous studies have indicated that tirzepatide is associated with greater glycemic control and weight reduction compared to semaglutide. Understanding the cardiovascular implications of these medications is crucial as T2D is associated with increased cardiovascular risk.
Methods
The study utilized the Research Collaborative Network of the TriNetX platform to analyze de-identified real-world data from patients with T2D. A total of 271,685 patients using tirzepatide were matched with 271,685 patients using semaglutide using one-to-one propensity score matching to control for confounding variables. The primary outcome was a composite of cardiovascular events including acute myocardial infarction, stroke, and acute heart failure, along with all-cause mortality.
Results
The primary composite outcome occurred in 4.6% of the tirzepatide group compared to 5.5% in the semaglutide group, resulting in an absolute risk difference of -0.9% (95% CI -1.01 to -0.77) and a hazard ratio of 0.9 (95% CI 0.92─0.96). All-cause mortality was 0.6% in the tirzepatide group versus 0.9% in the semaglutide group, with an absolute risk difference of -0.3% (95% CI -0.33 to -0.24) and a hazard ratio of 0.8 (95% CI 0.74─0.84).
Interpretation
The findings suggest that tirzepatide may offer a lower risk of cardiovascular events and all-cause mortality compared to semaglutide in patients with T2D. However, while the differences are statistically significant, the clinical significance should be evaluated in the context of overall patient management. Limitations include potential confounding factors inherent in real-world data and the lack of long-term follow-up.
Key findings
- 4.6% primary composite outcome in tirzepatide group vs. 5.5% in semaglutide group, ARD -0.9%, 95% CI -1.01 to -0.77, HR 0.9, 95% CI 0.92─0.96.
- 0.6% all-cause mortality in tirzepatide group vs. 0.9% in semaglutide group, ARD -0.3%, 95% CI -0.33 to -0.24, HR 0.8, 95% CI 0.74─0.84.
- N = 271,685 for each cohort.
Limitations
- Relies on real-world data, which may introduce confounding factors.
- No long-term effects reported.
- Single-site analysis.
- No clinical trial registration.